Simple and effective solutions in the correction of anxiety and stress

Acute and chronic stress conditions have an adverse effect on human health at any age and are related to the psychosocial risk factors for chronic non-communicable diseases, increasing the risk of occurrence and development of not only cardiovascular, but also other common diseases such as diabetes mellitus, obesity, broncho-obstructive diseases, ulcerative lesions of gastrointestinal tract, etc. The negative effect of stress on the human health is effectuated both through endogenous pathophysiological changes and through behavioural disorders such as physical inactivity, malnutrition, smoking, alcohol intake, etc. It has also been shown that psychosocial risk factors significantly aggravate the clinical course of existing diseases, significantly reduce adherence to treatment, worsen quality of life, increase the risk of disability and expenditures paid in the healthcare system in patients with chronic non-communicable diseases. Thus, acute and chronic stress have a negative effect on the physical, mental and emotional health, that's why the right choice of both preventive measures and timely management is very important. The combination of non-pharmaceutical effect, including training in stress resistance skills, proper response and emergency self-help in a stressful situation, with the prescription of effective pharmacological therapy can be considered as the optimal strategy. Valocordin® available in the form of drops or tablets represents a combination of low doses of phenobarbital with ethyl bromisovalerianate and plant components, which enhances the positive effects of the combination due to functional.

1. Alexandrovsky Yu.A., Neznanov N.G. (eds.). Psychiatry. National leadership. Moscow: GEOTAR-Media; 2020. 1008 p. (In Russ.)

2. Drapkina O.M., Kontsevaya A.V., Kalinina A.M., Avdeev S.M., Agaltsov M.V., Alexandrova L.M. et al. 2022 Prevention of chronic non-communicable diseases in the Russian Federation. National guidelines. Cardiovascular Therapy and Prevention. 2022;21(4):3235. (In Russ.) https://doi.org/10.15829/17288800-2022-3235.

3. Drapkina O.M., Shishkova V.M., Kotova M.B. Psychoemotional risk factors for non-communicable diseases in outpatient practice. Guidelines for internists. Cardiovascular Therapy and Prevention. 2022;21(10):3438. (In Russ.) https://doi.org/10.15829/1728-8800-2022-3438.

4. Shishkova V.N., Adasheva T.V. The relevance of screening for cognitive and psychoemotional disorders in patients with metabolic syndrome and insulin resistance: A review. Consilium Medicum. 2022;24(4):252–255. (In Russ.) https://doi.org/10.26442/20751753.2022.4.201681.

5. Shishkova V.N. Obesity as a reflection of psycho-emotional disorders: focus on pharmacotherapy. Farmatsiya i Farmakologiya. 2022;10(1):19–30. (In Russ.) https://doi.org/10.19163/2307-9266-2022-10-1-19-30.

6. Shishkova V.N., Kotova M.B., Kapustina L.A., Imamgayazova K.E. Issues of pathogenesis of cognitive and psychoemotional disorders in patients with cardiovascular and metabolic diseases. Therapy. 2021;50(8):158–163. (In Russ.) Available at: https://therapy-journal.ru/ru/archive/article/41008.

7. Pogosova N., Saner H., Pedersen S.S., Cupples M.E., McGee H., Höfer S. et al. Psychosocial aspects in cardiac rehabilitation: From theory to practice. A position paper from the Cardiac Rehabilitation Section of the European Association of Cardiovascular Prevention and Rehabilitation of the European Society of Cardiology. Eur J Prev Cardiol. 2015;22(10):1290–1306. https://doi.org/10.1177/2047487314543075.

8. Crawshaw J., Auyeung V., Norton S., Weinman J. Identifying psychosocial predictors of medication non-adherence following acute coronary syndrome: A systematic review and meta-analysis. J Psychosom Res. 2016;90:10–32. https://doi.org/10.1016/j.jpsychores.2016.09.003.

9. Kessing D., Denollet J., Widdershoven J., Kupper N. Psychological Determinants of Heart Failure Self-Care: Systematic Review and MetaAnalysis. Psychosom Med. 2016;78(4):412–431. https://doi.org/10.1097/PSY.0000000000000270.

10. Boehm J.K., Kubzansky L.D. The heart’s content: the association between positive psychological well-being and cardiovascular health. Psychol Bull. 2012;138(4):655–691. https://doi.org/10.1037/a0027448.

11. Müller-Riemenschneider F., Meinhard C., Damm K., Vauth C., Bockelbrink A., Greiner W., Willich S.N. Effectiveness of nonpharmacological secondary prevention of coronary heart disease. Eur J Cardiovasc Prev Rehabil. 2010;17(6):688–700. https://doi.org/10.1097/HJR.0b013e32833a1c95.

12. Orth-Gomér K., Schneiderman N., Wang H.X., Walldin C., Blom M., Jernberg T. Stress reduction prolongs life in women with coronary disease: the Stockholm Women’s Intervention Trial for Coronary Heart Disease (SWITCHD). Circ Cardiovasc Qual Outcomes. 2009;2(1):25–32. https://doi.org/10.1161/CIRCOUTCOMES.108.812859.

13. Gulliksson M., Burell G., Vessby B., Lundin L., Toss H., Svärdsudd K. Randomized controlled trial of cognitive behavioral therapy vs standard treatment to prevent recurrent cardiovascular events in patients with coronary heart disease: Secondary Prevention in Uppsala Primary Health Care project (SUPRIM). Arch Intern Med. 2011;171(2):134–140. https://doi.org/10.1001/archinternmed.2010.510.

14. Virgili M. Mindfulness-Based Interventions Reduce Psychological Distress in Working Adults: a Meta-Analysis of Intervention Studies. Mindfulness. 2015;6(2):326–337. https://doi.org/10.1007/s12671-013-0264-0.

15. Dehdari T., Heidarnia A., Ramezankhani A., Sadeghian S., Ghofranipour F. Effects of progressive muscular relaxation training on quality of life in anxious patients after coronary artery bypass graft surgery. Indian J Med Res. 2009;129(5):603–608. Available at: https://pubmed.ncbi.nlm.nih.gov/19675392/.

16. Shi L., Zhang D., Wang L., Zhuang J., Cook R., Chen L. Meditation and blood pressure: a meta-analysis of randomized clinical trials. J Hypertens. 2017;35(4):696–706. https://doi.org/10.1097/HJH.0000000000001217.

17. Blumenthal J.A., Sherwood A., Smith P.J., Watkins L., Mabe S., Kraus W.E. et al. Enhancing Cardiac Rehabilitation With Stress Management Training: A Randomized, Clinical Efficacy Trial. Circulation. 2016;133(14):1341–1350. https://doi.org/10.1161/CIRCULATIONAHA.115.018926.

18. Richards S.H., Anderson L., Jenkinson C.E., Whalley B., Rees K., Davies P. et al. Psychological interventions for coronary heart disease: Cochrane systematic review and meta-analysis. Eur J Prev Cardiol. 2018;25(3):247–259. https://doi.org/10.1177/2047487317739978.

19. Shishkova V.N., Nartsissov Ya.R., Titova V.Yu., Sheshegova E.V. Molecular mechanisms defining application of glycine and zinc combination in correction of stress and anxiety main manifestations. Farmatsiya i Farmakologiya. 2022;10(5):404–415. https://doi.org/10.19163/2307-92662022-10-5-404-415.

20. Shishkova V.N., Ustarbekova D.B., Shishkov V.A., Imamgayazova K.E., Kapustina L.A. Psycho-emotional disorders in chronic heart failure patients. Therapy. 2022;8(1):44–49. (In Russ.) https://doi.org/10.18565/therapy.2022.1.44-49.

21. Shavlovskaya O.A. Therapy of anxiety disorders with herbal drugs. Medical Alphabet. 2017;2(15):28–32. (In Russ.) Available at: https://www.med-alphabet.com/jour/article/view/185/.

22. Shavlovskaya О.A. Anxiety Therapy. Meditsinskiy Sovet. 2019;(6):42–46. (In Russ.) https://doi.org/10.21518/2079-701X-2019-6-42-46.

23. Kutashev V.A. Modern approach to the therapy for autonomic disorders in patients under stressful conditions. Meditsinskiy Sovet. 2018;(18):92–95. (In Russ.) https://doi.org/10.21518/2079-701X-2018-18-92-95.

24. Pierdomenico S.D., Pierdomenico A.M., Coccina F., Clement D.L., De Buyzere M.L., De Bacquer D.A. et al. Prognostic Value of Masked Uncontrolled Hypertension. Hypertension. 2018;72(4):862–869. https://doi.org/10.1161/HYPERTENSIONAHA.118.11499.

25. Gorshkov A.Yu., Fedorovich A.A., Drapkina O.M. Masked arterial hypertension: what is known and what expected to be learned? Profilakticheskaya Meditsina. 2020;23(6):143–150. (In Russ.) https://doi.org/10.17116/ profmed202023062143.

26. Landsbergis P.A., Travis A., Schnall P.L. Working conditions and masked hypertension. High Blood Press Cardiovasc Prev. 2013;20(2):69–76. https://doi.org/10.1007/s40292-013-0015-2.

27. Bakkali M.E., Aboudrar S., Dakka T., Benjelloun H. Autonomic dysregulation and phenobarbital in patients with masked primary hypertension. Heliyon. 2020;6(1):e03239. https://doi.org/10.1016/j.heliyon.2020.e03239.

28. GBD 2017 Disease and Injury Incidence and Prevalence Collaborators. Global, regional, and national incidence, prevalence, and years lived with disability for 354 diseases and injuries for 195 countries and territories, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet. 2018;392(10159):1789–1858. https://doi.org/10.1016/S01406736(18)32279-7.